CE153595
Project Grant
Overview
Grant Description
Community project funding/Congressionally directed spending - construction - The landscape of pharmaceutical manufacturing is rapidly evolving, with increasing demands for personalized medications, rapid prototyping, and flexible manufacturing processes.
Traditional manufacturing methods often lack the agility and flexibility required to meet these evolving needs efficiently.
On-demand pharmaceutical manufacturing offers a solution by enabling the production of small batches of medications tailored to individual patient requirements or specific health care needs.
These innovations will help us achieve health equity through access to medications and improved patient outcomes.
In line with our commitment to innovation and advancement in pharmaceutical research and development, we propose the acquisition of state-of-the-art equipment to enhance our capabilities in on-demand pharmaceutical manufacturing, including dosage form characterization and point-of-care compounding.
This investment will not only facilitate our research and development endeavors but also serve as a pivotal resource for meeting health care needs and training future pharmacists and pharmaceutical scientists.
Traditional manufacturing methods often lack the agility and flexibility required to meet these evolving needs efficiently.
On-demand pharmaceutical manufacturing offers a solution by enabling the production of small batches of medications tailored to individual patient requirements or specific health care needs.
These innovations will help us achieve health equity through access to medications and improved patient outcomes.
In line with our commitment to innovation and advancement in pharmaceutical research and development, we propose the acquisition of state-of-the-art equipment to enhance our capabilities in on-demand pharmaceutical manufacturing, including dosage form characterization and point-of-care compounding.
This investment will not only facilitate our research and development endeavors but also serve as a pivotal resource for meeting health care needs and training future pharmacists and pharmaceutical scientists.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Mississippi
United States
Geographic Scope
State-Wide
Related Opportunity
HRSA-24-110
The University Of Mississippi was awarded
Enhancing Pharmaceutical Manufacturing Capabilities Personalized Medications
Project Grant CE153595
worth $4,500,000
from the HRSA Office of Federal Assistance Management in September 2024 with work to be completed primarily in Mississippi United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.493 Congressional Directives.
Status
(Ongoing)
Last Modified 11/7/24
Period of Performance
9/30/24
Start Date
9/29/27
End Date
Funding Split
$4.5M
Federal Obligation
$0.0
Non-Federal Obligation
$4.5M
Total Obligated
Activity Timeline
Transaction History
Modifications to CE153595
Additional Detail
Award ID FAIN
CE153595
SAI Number
CE153595-2035437177
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Other
Awarding Office
75RJ00 HRSA OFFICE OF FEDERAL ASSISTANCE MANAGEMENT
Funding Office
75RR00 HRSA HEALTHCARE SYSTEMS BUREAU
Awardee UEI
G1THVER8BNL4
Awardee CAGE
4B836
Performance District
MS-90
Senators
Roger Wicker
Cindy Hyde-Smith
Cindy Hyde-Smith
Modified: 11/7/24